Page 53 - IMO-2-2

Innovative Medicines & Omics Alzheimer’s disease and clinical trials

82. Tampi RR, Forester BP, Agronin M. Aducanumab: Evidence doi: 10.3233/JAD-140741
from clinical trial data and controversies. Drugs Context. 93. Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in
2021;10.
early Alzheimer’s disease. N Engl J Med. 2023;388:9-21.
doi: 10.7573/dic.2021-7-3
doi: 10.1056/NEJMoa2212948
83. Bayer TA. Pyroglutamate Aβ cascade as drug target in 94. Green RC, Schneider LS, Amato DA, et al. Effect of
Alzheimer’s disease. Mol Psychiatry. 2022;27:1880-1885.
tarenflurbil on cognitive decline and activities of daily living
doi: 10.1038/s41380-021-01409-2 in patients with mild Alzheimer disease: A randomized
controlled trial. JAMA. 2009;302:2557-2564.
84. Irizarry MC, Sims JR, Lowe SL, et al. Safety, Pharmacokinetics
(PK), and Florbetapir F-18 Positron Emission Tomography doi: 10.1001/jama.2009.1866
(PET) after multiple dose administration of LY3002813, A 95. Valera E, Spencer B, Fields JA, et al. Combination of
β-amyloid plaque-specific antibody, in Alzheimer’s Disease alpha-synuclein immunotherapy with anti-inflammatory
(AD). Alzheimers Dement. 2016;12:P352-P353.
treatment in a transgenic mouse model of multiple system
doi: 10.1016/j.jalz.2016.06.665 atrophy. Acta Neuropathol Commun. 2017;5:2.
85. Bouter Y, Liekefeld H, Pichlo S, et al. Donanemab detects doi: 10.1186/s40478-016-0409-1
a minor fraction of amyloid-β plaques in post-mortem 96. Decourt B, Drumm-Gurnee D, Wilson J, et al. Poor safety
brain tissue of patients with Alzheimer’s disease and Down and tolerability hamper reaching a potentially therapeutic
syndrome. Acta Neuropathol. 2022;143:601-603.
dose in the use of thalidomide for Alzheimer’s disease:
doi: 10.1007/s00401-022-02418-3 Results from a double-blind, placebo-controlled trial. Curr
Alzheimer Res. 2017;14:403-411.
86. Shcherbinin S, Evans CD, Lu M, et al. Association of
amyloid reduction after donanemab treatment with tau doi: 10.2174/1567205014666170117141330
pathology and clinical outcomes: The TRAILBLAZER-ALZ 97. Rishton GM, Look GC, Ni ZJ, et al. Discovery of
randomized clinical trial. JAMA Neurol. 2022;79:1015-1024.
investigational drug CT1812, an antagonist of the sigma-2
doi: 10.1001/jamaneurol.2022.2793 receptor complex for Alzheimer’s disease. ACS Med Chem
Lett. 2021;12:1389-1395.
87. Pontecorvo MJ, Lu M, Burnham SC, et al. Association of
donanemab treatment with exploratory plasma biomarkers doi: 10.1021/acsmedchemlett.1c00048
in early symptomatic Alzheimer disease: A secondary 98. Grundman M, Morgan R, Lickliter JD, et al. A phase 1 clinical
analysis of the TRAILBLAZER-ALZ randomized clinical trial of the sigma-2 receptor complex allosteric antagonist
trial. JAMA Neurol. 2022;79:1250-1259.
CT1812, a novel therapeutic candidate for Alzheimer’s
doi: 10.1001/jamaneurol.2022.3392 disease. Alzheimers Dement (N Y). 2019;5:20-26.
88. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in doi: 10.1016/j.trci.2018.11.001
early Alzheimer’s disease. N Engl J Med. 2021;384:1691-1704.
99. Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ,
doi: 10.1056/NEJMoa2100708 Anisman H, Ferguson SS. Chronic pharmacological
mGluR5 inhibition prevents cognitive impairment and
89. Doggrell SA. Still grasping at straws: Donanemab in Alzheimer’s
disease. Expert Opin Investig Drugs. 2021;30:797-801. reduces pathogenesis in an Alzheimer disease mouse model.
Cell Rep. 2016;15:1859-1865.
doi: 10.1080/13543784.2021.1948010
doi: 10.1016/j.celrep.2016.04.077
90. US Food and Drug Administration. FDA Converts Novel
Alzheimer’s Disease Treatment to Traditional Approval- 100. Haas LT, Salazar SV, Smith LM, et al. Silent allosteric
action Follows Confrmatory Trial to Verify Clinical Benefit. modulation of mGluR5 maintains glutamate signaling
Maryland: US Food and Drug Administration; 2023. while rescuing Alzheimer’s mouse phenotypes. Cell
Rep. 2017;20:76-88.
91. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized,
double-blind, phase 2b proof-of-concept clinical trial in doi: 10.1016/j.celrep.2017.06.023
early Alzheimer’s disease with lecanemab, an anti-Aβ 101. Fang C, Hernandez P, Liow K, et al. Buntanetap, a novel
protofibril antibody. Alzheimers Res Ther. 2021;13:80. translational inhibitor of multiple neurotoxic proteins,
proves to be safe and promising in both Alzheimer’s and
doi: 10.1186/s13195-021-00813-8
Parkinson’s patients. J Prev Alzheimers Dis. 2023;10:25-33.
92. Tucker S, Moller C, Tegerstedt K, et al. The murine version
of BAN2401 (mAb158) selectively reduces amyloid-beta doi: 10.14283/jpad.2022.84
protofibrils in brain and cerebrospinal fluid of tg-ArcSwe 102. Lahiri DK, Chen D, Maloney B, et al. The experimental
mice. J Alzheimers Dis. 2015;43:575-588. Alzheimer’s disease drug posiphen [(+)-phenserine]

Volume 2 Issue 2 (2025) 47 doi: 10.36922/IMO025050007